Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07668817 · ClinicalTrials.gov registry record · NA
Tract Closure in PCNL
A NA study, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- NA
- Development phase
- 92
- Enrollment target
NCT07668817 is a NA study that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 92 participants.
The verdict
NCT07668817, a NA study, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- NA
- Development phase
- 92 participants
- Enrollment target
Study Summary
This is a prospective, randomized controlled trial evaluating the effect of a hemostatic agent on tract-related bleeding during percutaneous nephrolithotomy (PCNL). Patients undergoing standardized PCNL will be randomized to receive either application of a hemostatic agent or no agent during tract closure, following uniform balloon occlusion, complete aspiration, and irrigation-free endoscopic assessment. The researchers hypothesize that adjunctive hemostatic agent use reduces perioperative hemoglobin decline compared with balloon tamponade alone and improves tract-related hemostasis outcomes.
Interventions
- PROCEDURE Balloon Tamponade
- DEVICE Surgicel
- DEVICE Floseal
- DEVICE Surgiflo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07668817
The ClinicalTrials.gov registry entry for NCT07668817 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Balloon Tamponade is the first listed.
NCT07668817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07668817 about?
NCT07668817 is a clinical study titled "Tract Closure in PCNL". This is a prospective, randomized controlled trial evaluating the effect of a hemostatic agent on tract-related bleeding during percutaneous nephrolithotomy (PCNL). Patients undergoing standardized PCNL will be randomized to receive either application of a hemostatic agent or no agent during tract c...
What is the current status of trial NCT07668817?
This trial is currently recruiting. It is a NA study. The enrollment target is 92 participants. The study started on 2026-07. Estimated completion is 2028-06.
What interventions are being tested in trial NCT07668817?
The interventions under investigation include: Balloon Tamponade (PROCEDURE), Surgicel (DEVICE), Floseal (DEVICE), Surgiflo (DEVICE).
Who is sponsoring clinical trial NCT07668817?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.